201 related articles for article (PubMed ID: 9874269)
1. High doses of a helper-dependent adenoviral vector yield supraphysiological levels of alpha1-antitrypsin with negligible toxicity.
Morral N; Parks RJ; Zhou H; Langston C; Schiedner G; Quinones J; Graham FL; Kochanek S; Beaudet AL
Hum Gene Ther; 1998 Dec; 9(18):2709-16. PubMed ID: 9874269
[TBL] [Abstract][Full Text] [Related]
2. Persistent hepatic expression of human apo A-I after transfer with a helper-virus independent adenoviral vector.
Van Linthout S; Lusky M; Collen D; De Geest B
Gene Ther; 2002 Nov; 9(22):1520-8. PubMed ID: 12407424
[TBL] [Abstract][Full Text] [Related]
3. Immune responses to reporter proteins and high viral dose limit duration of expression with adenoviral vectors: comparison of E2a wild type and E2a deleted vectors.
Morral N; O'Neal W; Zhou H; Langston C; Beaudet A
Hum Gene Ther; 1997 Jul; 8(10):1275-86. PubMed ID: 9215744
[TBL] [Abstract][Full Text] [Related]
4. Use of a liver-specific promoter reduces immune response to the transgene in adenoviral vectors.
Pastore L; Morral N; Zhou H; Garcia R; Parks RJ; Kochanek S; Graham FL; Lee B; Beaudet AL
Hum Gene Ther; 1999 Jul; 10(11):1773-81. PubMed ID: 10446917
[TBL] [Abstract][Full Text] [Related]
5. Administration of helper-dependent adenoviral vectors and sequential delivery of different vector serotype for long-term liver-directed gene transfer in baboons.
Morral N; O'Neal W; Rice K; Leland M; Kaplan J; Piedra PA; Zhou H; Parks RJ; Velji R; Aguilar-Córdova E; Wadsworth S; Graham FL; Kochanek S; Carey KD; Beaudet AL
Proc Natl Acad Sci U S A; 1999 Oct; 96(22):12816-21. PubMed ID: 10536005
[TBL] [Abstract][Full Text] [Related]
6. Genomic DNA transfer with a high-capacity adenovirus vector results in improved in vivo gene expression and decreased toxicity.
Schiedner G; Morral N; Parks RJ; Wu Y; Koopmans SC; Langston C; Graham FL; Beaudet AL; Kochanek S
Nat Genet; 1998 Feb; 18(2):180-3. PubMed ID: 9462752
[TBL] [Abstract][Full Text] [Related]
7. Toxicity associated with repeated administration of first-generation adenovirus vectors does not occur with a helper-dependent vector.
O'Neal WK; Zhou H; Morral N; Langston C; Parks RJ; Graham FL; Kochanek S; Beaudet AL
Mol Med; 2000 Mar; 6(3):179-95. PubMed ID: 10965494
[TBL] [Abstract][Full Text] [Related]
8. Toxicological comparison of E2a-deleted and first-generation adenoviral vectors expressing alpha1-antitrypsin after systemic delivery.
O'Neal WK; Zhou H; Morral N; Aguilar-Cordova E; Pestaner J; Langston C; Mull B; Wang Y; Beaudet AL; Lee B
Hum Gene Ther; 1998 Jul; 9(11):1587-98. PubMed ID: 9694157
[TBL] [Abstract][Full Text] [Related]
9. Helper-dependent adenoviral vectors for gene therapy.
Palmer DJ; Ng P
Hum Gene Ther; 2005 Jan; 16(1):1-16. PubMed ID: 15703484
[TBL] [Abstract][Full Text] [Related]
10. [Advances in helper-dependent adenoviral vector--a review review].
Fu Y; He J; Shi C; Hong T
Wei Sheng Wu Xue Bao; 2009 Feb; 49(2):147-52. PubMed ID: 19445167
[TBL] [Abstract][Full Text] [Related]
11. Improved vascular gene transfer with a helper-dependent adenoviral vector.
Wen S; Graf S; Massey PG; Dichek DA
Circulation; 2004 Sep; 110(11):1484-91. PubMed ID: 15326058
[TBL] [Abstract][Full Text] [Related]
12. Effect of promoters and enhancers on expression, transgene DNA persistence, and hepatotoxicity after adenoviral gene transfer of human apolipoprotein A-I.
Van Linthout S; Collen D; De Geest B
Hum Gene Ther; 2002 May; 13(7):829-40. PubMed ID: 11975849
[TBL] [Abstract][Full Text] [Related]
13. Antigen-specific tolerance of human alpha1-antitrypsin induced by helper-dependent adenovirus.
Cerullo V; McCormack W; Seiler M; Mane V; Cela R; Clarke C; Rodgers JR; Lee B
Hum Gene Ther; 2007 Dec; 18(12):1215-24. PubMed ID: 18021020
[TBL] [Abstract][Full Text] [Related]
14. Development of a FLP/frt system for generating helper-dependent adenoviral vectors.
Ng P; Beauchamp C; Evelegh C; Parks R; Graham FL
Mol Ther; 2001 May; 3(5 Pt 1):809-15. PubMed ID: 11356086
[TBL] [Abstract][Full Text] [Related]
15. Therapeutic serum concentrations of human alpha-1-antitrypsin after adenoviral-mediated gene transfer into mouse hepatocytes.
Kay MA; Graham F; Leland F; Woo SL
Hepatology; 1995 Mar; 21(3):815-9. PubMed ID: 7875680
[TBL] [Abstract][Full Text] [Related]
16. Helper-dependent adenoviral vector-mediated long-term expression of human apolipoprotein A-I reduces atherosclerosis in apo E-deficient mice.
Pastore L; Belalcazar LM; Oka K; Cela R; Lee B; Chan L; Beaudet AL
Gene; 2004 Mar; 327(2):153-60. PubMed ID: 14980712
[TBL] [Abstract][Full Text] [Related]
17. Pseudo-hydrodynamic delivery of helper-dependent adenoviral vectors into non-human primates for liver-directed gene therapy.
Brunetti-Pierri N; Stapleton GE; Palmer DJ; Zuo Y; Mane VP; Finegold MJ; Beaudet AL; Leland MM; Mullins CE; Ng P
Mol Ther; 2007 Apr; 15(4):732-40. PubMed ID: 17285138
[TBL] [Abstract][Full Text] [Related]
18. Use of helper-dependent adenoviral vectors of alternative serotypes permits repeat vector administration.
Parks R; Evelegh C; Graham F
Gene Ther; 1999 Sep; 6(9):1565-73. PubMed ID: 10490766
[TBL] [Abstract][Full Text] [Related]
19. Advances in helper-dependent adenoviral vector research.
Segura MM; Alba R; Bosch A; Chillón M
Curr Gene Ther; 2008 Aug; 8(4):222-35. PubMed ID: 18691018
[TBL] [Abstract][Full Text] [Related]
20. Immune response to helper dependent adenoviral mediated liver gene therapy: challenges and prospects.
Seiler MP; Cerullo V; Lee B
Curr Gene Ther; 2007 Oct; 7(5):297-305. PubMed ID: 17979676
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
